Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165554 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
NCT01165554: Completed Phase 3 study, sponsored by GE Healthcare.
NCT01165554 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 203 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01165554, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
Study Summary
To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
Primary Outcome
A calculation used to assess Sensitivity was (Number of Blinded Reads determined abnormal by Reader "N") divided by the (Total number of abnormal participants). Blinded visual interpretations of \[18F\]flutemetamol Positron Emission Tomography (PET) images without anatomic brain images for detecting brain fibrillar amyloid β.
Interventions
- DRUG [18F] Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
What the finished NCT01165554 record still lists
NCT01165554 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F] Flutemetamol is the first listed.
NCT01165554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01165554 about?
NCT01165554 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels". To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
What is the current status of trial NCT01165554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2010-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01165554?
The interventions under investigation include: [18F] Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01165554?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01165554's enrollment target sits among peer trials
203 1352nd of 2000 higher than 648 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia